Interim Phase 1 INLIGHT trial data showed a single 240 mg dose of WVE-007 led to 4% total body fat reduction at 3 months, outperforming semaglutide's 2-2.5% at similar timepoint while preserving lean mass12
9.2% placebo-adjusted visceral fat reduction and 0.9% lean mass increase observed, with clean safety profile and no GI issues1
Wave shares surged 80% to $13.52 after announcement; analysts project $7B peak sales and call it disruptive1
Six-month data for 240 mg dose and additional data for higher doses expected in Q1 2026; Phase 2a multidose trial planned for H1 2026123
Preclinical studies showed weight loss similar to GLP-1s, doubled effect as semaglutide add-on, and prevented weight regain post-GLP-12
Sources:
1. https://www.biospace.com/drug-development/wave-soars-on-early-results-for-obesity-treatment-that-could-disrupt-the-landscape
2. https://www.globenewswire.com/news-release/2026/02/26/3245471/0/en/Wave-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html
3. https://www.investing.com/news/company-news/wave-life-sciences-to-expand-obesity-drug-trials-in-2026-93CH-4441798